Dr Reddy's Laboratories Cash Flow from Investing Activities 2010-2023 | RDY
Dr Reddy's Laboratories annual/quarterly cash flow from investing activities history and growth rate from 2010 to 2023. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
- Dr Reddy's Laboratories cash flow from investing activities for the quarter ending December 31, 2023 was $-0.348B, a 12.62% increase year-over-year.
- Dr Reddy's Laboratories cash flow from investing activities for the twelve months ending December 31, 2023 was $-1.105B, a 55.85% increase year-over-year.
- Dr Reddy's Laboratories annual cash flow from investing activities for 2023 was $-0.503B, a 44.54% increase from 2022.
- Dr Reddy's Laboratories annual cash flow from investing activities for 2022 was $-0.348B, a 12.26% increase from 2021.
- Dr Reddy's Laboratories annual cash flow from investing activities for 2021 was $-0.31B, a 376.92% increase from 2020.
Dr Reddy's Laboratories Annual Cash Flow Investing
(Millions of US $) |
| 2023 |
$-503 |
| 2022 |
$-348 |
| 2021 |
$-310 |
| 2020 |
$-65 |
| 2019 |
$-112 |
| 2018 |
$-229 |
| 2017 |
$-285 |
| 2016 |
$-308 |
| 2015 |
$-368 |
| 2014 |
$-277 |
| 2013 |
$-254 |
| 2012 |
$-367 |
| 2011 |
$-194 |
| 2010 |
$-156 |
| 2009 |
$-69 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$11.932B |
$3.350B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
